Angiogenesis Inhibitors: all 4,430 studies that test it

Page 23 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.

• A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver CancerActive, not recruitingNCT05211323Phase 2
• A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.WithdrawnNCT05205252Phase 1/2
• A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian CancerTerminatedNCT05200364Phase 1
• A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaStatus unknownNCT05200312Phase 2
• Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GCStatus unknownNCT05198856Phase 1/2
• GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) PatientsActive, not recruitingNCT05191784Phase 2
• A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple MyelomaWithdrawnNCT05183139Phase 4
• A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain MetastasisWithdrawnNCT05180422Phase 1/2
• Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyTerminatedNCT05180006Phase 2
• A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical CancerTerminatedNCT05179239Phase 3
• A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian CancerStatus unknownNCT05170594Phase 2
• To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLCCompletedNCT05169801Phase 3
• Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian CancerStatus unknownNCT05158062Phase 2
• A Study on the Treatment Strategy of NVG Secondary to PDRCompletedNCT05156021Not applicable
• Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)CompletedNCT05155293Phase 3
• A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal ImpairmentStatus unknownNCT05147493Phase 2
• A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-CancerStatus unknownNCT05132413Phase 3
• Clinical Experience of Thalidomide in Thalassemic PatientsCompletedNCT05132270Phase 2/3
• A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular DegenerationWithdrawnNCT05126966Phase 3
• Isa-RVD Study in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT05123131Phase 2
• An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)Active, not recruitingNCT05112965Phase 3
• A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal DisordersActive, not recruitingNCT05112861Phase 3
• Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male SubjectsCompletedNCT05110118Phase 1
• Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular CarcinomaWithdrawnNCT05109052Phase 1/2
• Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell LymphomasTerminatedNCT05105412Phase 1/2
• Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung CancerStatus unknownNCT05104281Phase 3
• Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.Active, not recruitingNCT05097911Phase 1
• SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular CarcinomaTerminatedNCT05093608Phase 1
• A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Phase 3
• Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsActive, not recruitingNCT05075993Phase 1
• CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal CancerWithdrawnNCT05070104Phase 1
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/3
• Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell LymphomaCompletedNCT05058755Not applicable
• Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract CancerCompletedNCT05052099Phase 1/2
• Marizomib Central Nervous System (CNS)WithdrawnNCT05050305Phase 2
• Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian CancerCompletedNCT05044871Phase 2
• Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of PrematurityStatus unknownNCT05033106Phase 3
• HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCCStatus unknownNCT05029973Phase 2
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV BevacizumabActive, not recruitingNCT05029882Phase 1
• ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin LymphomaActive, not recruitingNCT05025800Phase 1/2
• Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell LymphomaStatus unknownNCT05014100Phase 2
• Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLCWithdrawnNCT05007769Phase 2
• Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLCCompletedNCT04997382Phase 2
• Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular EdemaTerminatedNCT04991350Phase 4
• Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal CancerStatus unknownNCT04988191Phase 1/2
• Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop StudyActive, not recruitingNCT04978584Phase 2
• Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical CancerStatus unknownNCT04973904Phase 2
• Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular GlaucomaCompletedNCT04970251Not applicable
• Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLCActive, not recruitingNCT04958811Phase 2
• Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 PatientsTerminatedNCT04954014Phase 2
• Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)TerminatedNCT04952571Phase 2
• Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor ThrombosisStatus unknownNCT04947826Phase 2
• Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal MetastasisStatus unknownNCT04944069Not applicable
• PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based ChemotherapyStatus unknownNCT04942301Phase 1
• Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM PatientsActive, not recruitingNCT04940546Phase 1/2
• Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerActive, not recruitingNCT04938583Phase 1/2
• Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System LymphomaCompletedNCT04934579Phase 2
• Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMDActive, not recruitingNCT04932980Not applicable
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
• Lenalidomide and Dexamethasone for Rosai-Dorfman DiseaseStatus unknownNCT04924647Phase 2
• Daratumumab and Pomalidomide in Previously Treated Patients With AL AmyloidosisTerminatedNCT04895917Phase 2
• Selinexor in Combination With Thalidomide and Dexamethasone in RRMMStatus unknownNCT04891744Phase 1/2
• Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)Status unknownNCT04888663Phase 1/2
• Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMDCompletedNCT04884399Phase 1
• Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04883242Phase 2
• BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular DegenerationStatus unknownNCT04882956Not applicable
• Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell TransplantActive, not recruitingNCT04876248Phase 2
• SBRT + Atezolizumab + Bevacizumab in Resectable HCCActive, not recruitingNCT04857684Early Phase 1
• A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRCTerminatedNCT04856787Phase 2/3
• Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04850599Phase 2
• Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCCStatus unknownNCT04843943Phase 1/2
• Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung CancerActive, not recruitingNCT04837716Phase 1
• Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsActive, not recruitingNCT04824092Phase 3
• Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCLStatus unknownNCT04796857Phase 1/2
• Study of Selinexor Plus DRd for Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04782687Phase 2
• Evaluation of RC28-E Injection in Diabetic RetinopathyStatus unknownNCT04782128Phase 2
• Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaBActive, not recruitingNCT04776655Phase 3
• DARA RVD For High Risk SMMActive, not recruitingNCT04775550Phase 2
• The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple MyelomaStatus unknownNCT04762745Phase 1/2
• Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal CancerCompletedNCT04761614Phase 1
• 131I-Omburtamab, in Recurrent Medulloblastoma and EpendymomaActive, not recruitingNCT04743661Phase 2
• Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04741165Phase 2
• A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMDCompletedNCT04740671Phase 3
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
• Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)CompletedNCT04739202Phase 2
• A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast CancerCompletedNCT04732598Phase 3
• Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung CancerCompletedNCT04730999Phase 2
• Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II TrialActive, not recruitingNCT04727307Phase 2
• Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid CarcinomaStatus unknownNCT04725448Phase 2
• Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaActive, not recruitingNCT04724239Phase 2
• Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver CancerActive, not recruitingNCT04721132Phase 2
• Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM PatientsActive, not recruitingNCT04717700Phase 2
• Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA TrialCompletedNCT04708145Phase 4
• Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving AfliberceptStatus unknownNCT04707027Not applicable
• Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the EyeWithdrawnNCT04702048Phase 4
• Endostar Combined With AI Regimen Compared With AI in Adjuvant TreatmentStatus unknownNCT04699214Phase 2
• Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal CancerStatus unknownNCT04683965Phase 2
• Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative ResectionStatus unknownNCT04682210Phase 3
• Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and BevacizumabTerminatedNCT04681677Phase 2
• Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable BleedingStatus unknownNCT04680195Phase 2

← Angiogenesis Inhibitors overview